其中行术后辅助化疗20例，因局部晚期或复发、转移行姑息化疗62例。
We had 20 patients receiving adjuvant chemotherapy and 62 patients of local-advanced or with tumor recurrence or metastasis receiving palliative chemotherapy.
目的研究延期留置空肠穿刺造口管间断肠内营养在进展期胃癌术后辅助化疗中应用的可行性及其临床疗效。
Objective to study the feasibility and clinical effects of enteral nutrition by needle catheter jejunostomy (NCJ) tube in the postoperative adjuvant chemotherapy for patients of staged gastric cancer.
方法搜集1983年至1994年采用手术加术后辅助化疗的小细胞肺癌65例，其中行脑预防照射22例。
Methods From 1983 to 1994, 65 patients with SCLC were treated by surgery combined with postoperative chemotherapy, and 22 of them received prophylactic cranial irradiation.
结论含紫杉醇类药物进行术后辅助化疗能增加HER - 2阳性乳腺癌患者无病生存获益，尤其是对ER、PR均阴性且her - 2阳性者。
Conclusions Adjuvant chemotherapy containing paclitaxel can improve the disease-free survival of breast cancer with HER-2 positive, especially for the patients with er and pr negative.
结论；根据所有的相关rct研究可以看出，术后氟尿嘧啶为基础的辅助化疗与单纯手术相比较能够减少可切除胃癌患者的死亡风险。
Conclusion Among the RCTs included, postoperative adjuvant chemotherapy based on fluorouracil regimens was associated with reduced risk of death in gastric cancer compared with surgery alone.
目的探讨术前新辅助化疗对乳腺癌的疗效及提高患者术后生存率的作用。
To explore the effect of new auxiliary chemotherapy before operation on treating local mammary cancer of late stage and prolonging the life of the cancer patients.
结论术前新辅助化疗可提高食管癌手术的切除率并不增加术后并发症。
Conclusion Patients of esophageal carcinoma, neoadjuvant chemotherapy can increased the resectability rate, meanwhile cannot increase postoperative complications and mortality.
术后常规行辅助放疗、化疗和内分泌治疗。
Routine adjuvant irradiation, chemotherapy and hormone therapy were given postoperatively.
结论术后给予4 ~6个疗程的辅助化疗较为合适。
Conclusion the postoperative chemotherapy with 4 to 6 courses is appropriate.
目的探讨胃癌根治术后应用辅助化疗患者的远期疗效。
Objective To discuss the long term curative effect of adjuvant FAM chemotherapy after radical operation of gastric carcinoma.
目的通过研究新辅助化疗对乳腺癌根治术后病理分期及治疗方案的影响，进一步评价新辅助化疗的临床价值。
Objective To evaluate the clinical value of neoadjuvant chemotherapy for breast cancer on pathological stage and designing of therapy plan.
术后常规行辅助放疗、化疗和内分泌治疗。
Adjuvant irradiation, chemotherapy and hormone therapy were given postoperatively.
目的探讨肝癌合并门静脉癌栓的手术疗效，评价术中门静脉癌栓取出术和术后辅助肝动脉栓塞化疗对提高肝癌术后生存率的影响。
Objective To explore the value of removing portal vein tumor thrombus (PVTT) and TACE in improving the outcome of resection for primary liver cancer with PVTT.
术前辅以新辅助化疗，术后辅以正规内分泌治疗是提高局部晚期乳腺癌生存率的必要手段。
The neoadjuvant chemotherapy and regular endocrine therapy are the necessary measures to improve the survival rates of locally advanced breast cancer.
结论肝移植术后辅助个体化化疗能显著降低肝癌肝移植术后的肿瘤复发率 ，明显延长肝移植术后的无瘤生存时间。
Conclusions This study suggests that tumor recurrence decreases and tumor free survival increases by adjuvant individualized chemotherapy after liver transplantation for HCC.
术中或术后早期应给辅助性腹腔内化疗，并配合放疗及BRM辅助治疗。
Intraoperative or postoperative adjuvant to be intraperitoneal chemotherapy, and radiotherapy and BRM with adjuvant therapy.
结论腹腔超体温热化疗可作为中、晚期胃癌术后的一种有效、安全的辅助治疗。
Conclusion Warm chemotherapy could be used for the metaphase and late stage gastric carcinoma cases.
重组人血管内皮抑素联合TP方案术后辅助治疗NSCLC较单纯化疗显示近期疗效上的优势、长期生存结果值得期待。
The effect endostatin combined with TP seem to be superior to TP alone in some short term index for the treatment of postoperative NSCLC even though long-term survival is still anticipated.
重组人血管内皮抑素联合TP方案术后辅助治疗NSCLC较单纯化疗显示近期疗效上的优势、长期生存结果值得期待。
The effect endostatin combined with TP seem to be superior to TP alone in some short term index for the treatment of postoperative NSCLC even though long-term survival is still anticipated.
应用推荐